| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Livmoniplimab | MGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115 | Phase 3 Clinical | Argenx Se | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours | Details |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center) | Phase 1 Clinical | Ohio State University Comprehensive Cancer Center | Glioma | Details | |
| PBA-0111 | PBA-0111 | Phase 1 Clinical | Pure Biologics SA | Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| HLX-6018 | HLX-6018; HLX6018 | Phase 1 Clinical | Idiopathic Pulmonary Fibrosis | Details | |
| JYB-1907 | JYB-1907 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Solid tumours | Details |
| DS-1055 | DS-1055; DS-1055a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Neoplasms; Solid tumours | Details |
| HLX-60 | HLX-60 | Phase 1 Clinical | Lymphoma; Solid tumours | Details |